Financials Alvotech Nyse

Equities

ALVO

LU2458332611

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 01:30:00 18/07/2024 am IST			5-day change	1st Jan Change
11.98 ^USD	-1.32%		+1.08%	+27.72%

11/07	Alvotech Closes $965 Million Loan Facility	MT
11/07	Alvotech Closes $965 Million Loan Facility	MT

Valuation

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Capitalization ¹	308.8	2,486	3,048	3,662	-	-
Enterprise Value (EV) ¹	308.8	3,165	3,959	4,861	4,943	4,411
P/E ratio	-0.8 x	-3.85 x	-4.72 x	-23.6 x	85.7 x	16.9 x
Yield	-	-	-	-	-	-
Capitalization / Revenue	8.4 x	29.9 x	32.6 x	9.03 x	5.97 x	4.52 x
EV / Revenue	8.4 x	38.1 x	42.4 x	12 x	8.06 x	5.45 x
EV / EBITDA	-	-9.71 x	-12 x	48.2 x	14 x	9.18 x
EV / FCF	-	-9.04 x	-11.5 x	43 x	25.6 x	12.1 x
FCF Yield	-	-11.1%	-8.72%	2.32%	3.9%	8.28%
Price to Book	-	-4.41 x	-2.8 x	-2.4 x	-3.76 x	-11.7 x
Nbr of stocks (in thousands)	31,250	2,48,650	2,65,530	3,01,640	-	-
Reference price ²	9.880	10.00	11.48	12.14	12.14	12.14
Announcement Date	10/05/22	01/03/23	20/03/24	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Net sales ¹	36.77	83.03	93.38	405.5	613.5	809.8
EBITDA ¹	-	-326	-330.6	100.9	354.3	480.5
EBIT ¹	-	-346.4	-354.9	61.76	234.6	412.9
Operating Margin	-	-417.25%	-380.01%	15.23%	38.24%	50.99%
Earnings before Tax (EBT) ¹	-	-551.6	-651	-159.2	46.07	241.3
Net income ¹	-	-513.6	-551.7	-127.2	41.19	193
Net margin	-	-618.55%	-590.83%	-31.36%	6.71%	23.83%
EPS ²	-12.29	-2.600	-2.430	-0.5142	0.1416	0.7168
Free Cash Flow ¹	-	-350.3	-345.4	113	193	365
FCF margin	-	-421.86%	-369.9%	27.87%	31.46%	45.07%
FCF Conversion (EBITDA)	-	-	-	112%	54.47%	75.96%
FCF Conversion (Net income)	-	-	-	-	468.55%	189.12%
Dividend per Share ²	-	-	-	-	-	-
Announcement Date	10/05/22	01/03/23	20/03/24	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2023 Q2
Net sales	-
EBITDA	-
EBIT	-
Operating Margin	-
Earnings before Tax (EBT)	-
Net income ¹	189.3
Net margin	-
EPS ²	0.8500
Dividend per Share	-
Announcement Date	30/08/23

¹USD in Million²USD

Estimates

Balance Sheet Analysis

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	678	911	1,199	1,281	749
Net Cash position ¹	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-2.08 x	-2.755 x	11.88 x	3.614 x	1.558 x
Free Cash Flow ¹	-	-350	-345	113	193	365
ROE (net income / shareholders' equity)	-	-	-	-	-	-
ROA (Net income/ Total Assets)	-	-72%	-62%	-12.1%	5.34%	13.9%
Assets ¹	-	713.2	889.3	1,049	771.4	1,393
Book Value Per Share ²	-	-2.270	-4.100	-5.060	-3.230	-1.040
Cash Flow per Share ²	-	-1.580	-1.370	0.2000	1.350	2.020
Capex ¹	-	37.9	33.2	34.4	8.51	8.51
Capex / Sales	-	45.62%	35.59%	8.48%	1.39%	1.05%
Announcement Date	10/05/22	01/03/23	20/03/24	-	-	-

¹USD in Million²USD

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Alvotech

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

11.98 USD

Average target price

17.5 USD

Spread / Average Target

+46.08%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+24.74%	4.8TCr
IQVIA HOLDINGS INC.	-0.47%	4.24TCr
LONZA GROUP AG	+43.96%	4.15TCr
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	3.16TCr
ICON PUBLIC LIMITED COMPANY	+17.96%	2.86TCr
CELLTRION, INC.	-4.47%	2.8TCr
UNITED THERAPEUTICS CORPORATION	+50.73%	1.46TCr
MEDPACE HOLDINGS, INC.	+42.56%	1.41TCr
BIO-TECHNE CORPORATION	+1.46%	1.26TCr

Other Biotechnology & Medical Research